温肾通络止痛方治疗骨质疏松症临床分析  

Clinical Analysis of Wenshen Tongluo Zhitong Decoction in Treating Osteoporosis

作　　者：周信[1] 马庆宏[1] 郭杨[2] 马勇[2] ZHOU Xin;MA Qing-hong;GUO Yang;MA Yong(Department of Orthopedics,Nanjing Jiangning Hospital,Nanjing,Jiangsu Province,211000 China;The First Clinical Medical College,Nanjing University of Chinese Medicine,Nanjing,Jiangsu Province,210029 China)

机构地区：[1]南京市江宁医院骨科,江苏南京211100 [2]南京中医药大学第一临床医学院,江苏南京210029

出　　处：《中外医疗》2020年第30期157-160,166,共5页China & Foreign Medical Treatment

摘　　要：目的观察温肾通络止痛方治疗骨质疏松症的临床效果,总结分析其组方特点,进一步指导临床。方法方便选取2018年1月-2019年12月于南京市江宁医院门诊就诊的100例骨质疏松症患者,依据治疗方案的不同,分为两组,每组50例,对照组应用钙尔奇D联合阿法骨化醇治疗,观察组在对照组的基础上服用温肾通络止痛方治疗,比较两组临床效果、中医症候积分及治疗前后骨密度(BMD)及疼痛视觉模拟评分(VAS)。结果观察组有效率84%,明显高于对照组的64%,差异有统计学意义(χ^2=5.198,P=0.023);治疗后观察组患者的中医证候积分(10.54±0.51)分,对照组(16.25±0.41)分,两组较治疗前中医证候积分均显著下降(对照组:t=81.821,P<0.01;观察组:t=77.254,P<0.01),观察组与对照组相比较差异有统计学意义(t=61.702,P<0.01);治疗后观察组患者的BMD值(0.76±0.03)g/cm^3,对照组(0.69±0.12)g/cm^2,观察组较治疗前有明显提高,差异有统计学意义(t=6.420,P<0.01),与对照组相比差异有统计学意义(t=4.002,P<0.01);治疗后观察组VAS评分(1.25±0.41)分,对照组(3.53±0.56)分,两组较治疗前均有明显下降,差异有统计学意义(对照组:t=37.691,P<0.01;观察组:t=31.327,P<0.01),且观察组较对照组结果更加显著,差异有统计学意义(t=23.230,P<0.01)。结论温肾通络止痛方治疗骨质疏松症,能够提高患者骨密度,改善患者疼痛,缓解患者症状,具有良好的临床疗效。Objective To observe the clinical effects of Wenshen Tongluo Zhitong Decoction in the treatment of osteoporosis,summarize and analyze the characteristics of its prescriptions,and further guide the clinic.Methods A total of100 patients with osteoporosis who were treated in the Nanjing Jiangning Hospital outpatient clinic from January 2018 to December 2019 were convenient selected and divided into 2 groups according to different treatment plans,each with 50 cases.The control group was treated with Calci D combined with A in the treatment of calcium calciferol,the observation group was treated with Wenshen Tongluo Zhitong Decoction on the basis of the control group.The clinical effects,TCM syndrome scores,bone mineral density(BMD)and pain visual analog score(VAS)before and after treatment were compared between the two groups.Results The effective rate of the observation group was 84%,which was significantly higher than64%of the control group.The difference was statistically significant(χ^2=5.198,P=0.023);after treatment,the TCM syndrome score of the observation group was(10.54±0.51)points,compared the control group(16.25±0.41)points.Compared with the pre-treatment TCM syndrome scores,both groups were significantly lower(control group:t=81.821,P<0.01;observation group:t=77.254,P<0.01).The observation group was similar to the control group.The difference was statistically significant(t=61.702,P<0.01);the BMD value of the observation group after treatment(0.76±0.03)g/cm^3,the control group(0.69±0.12)g/cm^2,the observation group was better than the treatment There was a significant increase before,and the difference was statistically significant(t=6.420,P<0.01),compared with the control group(t=4.002,P<0.01);the observation group VAS score after treatment(1.25±0.41)points,the control group:(3.53±0.56)points,the two groups were significantly lower than before treatment,the difference was statistically significant(control group:t=37.691,P<0.01;observation group:t=31.327,P<0.01),and the observation group was more si

关 键 词：骨质疏松症 温肾通络止痛方 中医药 

分 类 号：R4[医药卫生—临床医学]